“… [ 84 ] | E. tenella | Inhibits the replication of by 75%, 50%, and 30% at the doses of 21.43 μg/mL, 5.28μg/mL, and 0.96μg/mL, respectively. | [ 86 ] |
Bone protection | RAW264.7 cells were exposed to 1, 2, and 5 μM glabridin | Increases the activity of TRAF6, GAB2, ERK2, JNK1, and MKK7, enhances the expression of c-FOS and NFATc1, and elevates the productions of MMP-9, cathepsin K, CAII, TCIRG1, OSTM1, and CLCN7. | [ 87 ] |
C2C12 cells were exposed to 10 μM glabridin | Abolishes dexamethasone-stimulated protein degradation | [ 88 ] |
L6 myotubes were exposed to 3, 10, and 30 μM glabridin | Stimulates AMPK-dependent GLUT4 translocation | [ 89 ] |
| MC3T3-E1 cells were exposed to 0.01, 0.1, and 1 μM glabridin | Inhibits MG-induced cytotoxicity and cell death | [ 90 ] |
MC3T3-E1 cells were exposed to 5 μM glabridin | Ameliorates dRib-induced oxidative damage and increases ALP, OPN, OPG, OC, and BMPs expression by up regulating the expression of PI3K/AKT2 signaling pathway | [ 91 ] |
MSCs were exposed to 1, 10, and 50 μM glabridin | Increases the expression of Oct4, Dlx5, Runx5, Osteocalcin, and Osteopontin | [ 96 ] |
Cardiovascular protection | Male New Zealand Rabbits receive 2 mg/kg glabridin by oral catheter for 6 weeks | Down regulation of MLCK/phosphorylated MLC system through MAPK signaling | [ 21 ] |
ECV-304 cells were exposed to 30 and 3000 nM glabridin | Increases DNA synthesis, exhibits a bi-phasic effect on the proliferation of VSMC | [ 100 ] |
Colonic macrophages from DOX-treated male C57BL/6 mice were exposed to 15 and 30 μM glabridin | Prevents against DOX-induced dysbiosis by modulating LPS/NF-κB and butyrate-STAT6 signaling | |
…”